Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Rheumatoid Arthritis: Update Bulletin [June 2014]

Product Code:
596200268
Release Date:
June 2014
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Rheumatoid Arthritis: European Medicines Agency (EMA) approves Roche's subcutaneous formulation of tocilizumab (RoACTEMRA)

Highlights from this event update bulletin

  • What are the benefits seen with Roche’s subcutaneous formulation of RoACTEMRA (tocilizumab) receiving EMA approval?
  • What are KOL views on the Intravenous Simponi application being withdrawn in Europe?
  • How will Anti-IL6 monoclonals compete with tocilizumab?
  • What impact does Xeljanz’s US label expansion including radiographic data have on confidence?
  • How are biosimilars viewed in the EU and US?
  • What needs to happen for Xeljanz to be launched in EU?
  • What impact will JAK inhibitors have in the industry? 

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved